Image Rotator

Any individual with a rare, uncommon, or unknown disorder is invited to join the CoRDS Registry and help accelerate research into rare conditions.
Join CoRDS. Help accelerate research.
Any individual with a rare, uncommon, or unknown disorder is invited to join the CoRDS Registry and help accelerate research into rare conditions.

 

The CoRDS Program Continues to Grow

Welcome to the Coordination of Rare Diseases at Sanford (CoRDS)!

Based at Sanford Research, a not-for-profit research institution, CoRDS is a centralized international patient registry for all rare diseases. The goal of the CoRDS registry is to connect as many patients and researchers as possible to help advance treatments and cures for rare diseases. The CoRDS registry is free for patients to enroll and for researchers to access. We work with patient advocacy groups, individuals, and researchers to coordinate the advancement of research into the 7,000 rare diseases.

 

 

The CoRDS Patient Enrollment System is scheduled for maintenance this Sunday, July 31st and will not be available from 11PM to 1AM CST. Thank you for your patience.

Our Solution

How does enrollment in the CoRDS Registry work?

Complete your screening form and receive login information.

 

 
 

Review informed consent and complete questionnaire to become fully enrolled. You will be asked to update this information annually.

 

Anticipate being contacted for potential research and clinical trial opportunities.

 

 

Get Registered

Twitter Updates on Sanford CoRDS
  • @SanfordCoRDS
    #PrecisionMedicine Initiative granted @NIH $130 million w/ $230 million reqested for future #health #research https://t.co/KBFddjTtRN

  • @SanfordCoRDS
    ND child hospitalized w/ #raredisease which is most prevalent in rural areas #Rodents #Hantavirus #PulmonarySyndrome https://t.co/LF4eykqwx8

  • @slopeio
    RT @ACROhealth: Survey shows #wearables tech & #socialmedia recruitment are two major #clinicaltrial trends https://t.co/ACEmLoB1bW https:/…

  • @ACROhealth
    Survey shows #wearables tech & #socialmedia recruitment are two major #clinicaltrial trends https://t.co/ACEmLoB1bW https://t.co/aeyp5o8LrD

  • @SanfordCoRDS
    Trinity is the 1st female in world with #raredisease #TibialAplasia #polydactyly #brachyphalangy https://t.co/0lYDwQavR7

  • @SanfordCoRDS
    The @US_FDA grants priority review status to #BioMarin for #BattenDisease #RareDisease #CLN2 https://t.co/VbzH9V7bqw

  • @kdcloer
    RT @Rose_of_Sharon8: Klippel-Feil Syndrome Awareness Day! Aug 6 @RareDR @GlobalGenes @SanfordCoRDS @RareAdvocates follow me @ #periscope ht…

  • @SanfordCoRDS
    RT @RareGenomics: RGI is happy to provide whole genome sequencing & analysis - email patient-team@raregenomics.org to learn more! https://t…

  • @SanfordCoRDS
    Boy, With #RareDisease Saved By 'Life Saving' #BoneMarrow #Transplant @AplasticAnaemia @BeTheMatch https://t.co/6PcvCuVj1G

  • @SanfordCoRDS
    These families who share a #raredisease #ataxia just gathered for an international reunion @NAF_Ataxia @CureFA_org https://t.co/j50R9o1KmG

  • @SanfordCoRDS
    RT @RareDR: BioMarin's BLA for Batten Disease Drug Accepted by the FDA https://t.co/lRaDEticBI $BMRN @BattenDisease @BDSRA https://t.co/bKQ…

  • @SanfordCoRDS
    .@pfizer, NEA-backed #raredisease startup funded $42M in funding for #NiemannPick Type C #clinicaltrial @NPCFund https://t.co/jS7HvQ9q79

  • @DrDavidPearce
    RT @RareDR: First Patient Dosed in Zika Vaccine Clinical Trial https://t.co/eGUqVI8bLe https://t.co/AwiXjTlzkc

  • @DrDavidPearce
    FDA Accepts BLA for BioMarin’s Cerliponase Alfa for CLN2 Disease, Form of Batten Disease https://t.co/FzcnkyP5oW #rarediseases

  • @WallaceUofE
    The latest The Rare diseases Daily! https://t.co/ht6gh6yNNu Thanks to @LitChick79 @JeffreyMcMurtry @SanfordCoRDS #raredisease #patients